Article
Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation.
Internal medicine (Tokyo, Japan) - 1 Sept 2020
Makimoto Go, Nishi Tatsuya, Kawakado Keita, Nishimura Tomoka, Tamura Tomoki, Kudo Kenichiro, Kuyama Shoichi
Abstract excerpt
Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.